Found 1 Presentation For Request "1285P"
1285P - Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study
- Johan F. Vansteenkiste (Leuven, Belgium)
Abstract
Background
Methods
Cohort 4 (pre-treated
Results
As of 28 October 2019, 69 pts with
Conclusions
Efficacy data of IO in pts with
Clinical trial identification
NCT02414139.
Editorial acknowledgement
Medical editorial assistance with this abstract was provided by Manojkumar Patel (Novartis Healthcare Pvt. Ltd).
Legal entity responsible for the study
Novartis.
Funding
Novartis Pharmaceuticals Corporation.
Disclosure
J.F. Vansteenkiste: Honoraria (self), Advisory/Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: MSD Oncology; Advisory/Consultancy: Novartis; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Merck Serono; Advisory/Consultancy: Roche; Research grant/Funding (institution): MSD. E.F. Smit: Advisory/Consultancy: Lilly; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution): Boehringer Ingelheim; Advisory/Consultancy, Research grant/Funding (institution): Roche/Genentech; Advisory/Consultancy, Research grant/Funding (institution): Bristol-Myers Squibb; Advisory/Consultancy: Merck KGaA; Advisory/Consultancy: MSD Oncology; Advisory/Consultancy: Takeda; Advisory/Consultancy, Research grant/Funding (institution): Bayer; Advisory/Consultancy: Regeneron; Advisory/Consultancy: Novartis; Advisory/Consultancy: Daiichi Sankyo; Advisory/Consultancy: Seattle Genetics. H.J.M. Groen: Advisory/Consultancy, Research grant/Funding (institution): Eli Lilly; Advisory/Consultancy: Novartis; Advisory/Consultancy: BMS; Advisory/Consultancy: Merck; Advisory/Consultancy: AbbVie; Research grant/Funding (institution): Boehringer Ingelheim. E.B. Garon: Advisory/Consultancy: Dracen; Advisory/Consultancy: EMD Serono; Advisory/Consultancy, Research grant/Funding (institution): Novartis; Research grant/Funding (institution): Merck; Research grant/Funding (institution): Genentech; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Lilly; Research grant/Funding (institution): Bristol-Myers Squibb; Research grant/Funding (institution): Mirati ; Research grant/Funding (institution): Dynavax; Research grant/Funding (institution): Iovance Biotherapeutics; Research grant/Funding (institution): Neon Therapeutics; Research grant/Funding (institution): EMD Serono. R.S. Heist: Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Research grant/Funding (institution): Tarveda ; Research grant/Funding (institution): Apollomics; Honoraria (self): Chugai/Roche; Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): Roche; Research grant/Funding (institution): Incyte; Research grant/Funding (institution): Celgene; Research grant/Funding (institution): Mirati Therapeutics; Research grant/Funding (institution): Peregrine Pharmaceuticals; Research grant/Funding (institution): Exelixis; Research grant/Funding (institution): Millennium; Research grant/Funding (institution): Debiopharm Group; Research grant/Funding (institution): Corvus Pharmaceuticals; Research grant/Funding (institution): Daiichi Sankyo; Research grant/Funding (institution): Agios; Research grant/Funding (institution): Pfizer. T. Hida: Honoraria (self), Research grant/Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant/Funding (institution): Chugai Pharma; Honoraria (self), Research grant/Funding (institution): Lilly; Honoraria (self), Research grant/Funding (institution): Novartis; Honoraria (self), Research grant/Funding (institution): Taiho Pharmaceutical; Honoraria (self), Research grant/Funding (institution): AstraZeneca; Honoraria (self), Research grant/Funding (institution): Nippon Boehringer Ingelheim; Honoraria (self), Research grant/Funding (institution): Pfizer; Honoraria (self), Research grant/Funding (institution): Bristol-Myers Squibb; Honoraria (self), Research grant/Funding (institution): Clovis Oncology; Honoraria (self), Research grant/Funding (institution): MSD; Honoraria (self), Research grant/Funding (institution): Kissei Pharmaceutical; Research grant/Funding (institution): Eisai; Research grant/Funding (institution): Takeda; Research grant/Funding (institution): Sumitomo Dainippon Pharma; Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): Merck Serono; Research grant/Funding (institution): Kyowa Hakko Kirin; Research grant/Funding (institution): Daiichi Sankyo; Research grant/Funding (institution): Astellas Pharma; Research grant/Funding (institution): Servier; Research grant/Funding (institution): Ignyta; Research grant/Funding (institution): Janssen. M. Nishio: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Novartis; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Ono Pharmaceutical; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Chugai Pharma; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Taiho Pharmaceutical; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Bristol-Myers Squibb Japan; Advisory/Consultancy: Daiichi Sankyo; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Lilly; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): MSD; Advisory/Consultancy: AbbVie; Advisory/Consultancy: Takeda; Advisory/Consultancy: Teijin Pharma; Honoraria (self), Research grant/Funding (institution): Pfizer; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Nippon Kayaku; Research grant/Funding (institution): Merck. K. Kokowski: Advisory/Consultancy, Travel/Accommodation/Expenses: Boehringer; Advisory/Consultancy: BMS; Travel/Accommodation/Expenses: Celgene. C. Grohe: Honoraria (self), Advisory/Consultancy: MSD Oncology; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Boehringer Ingelheim; Travel/Accommodation/Expenses: Roche; Travel/Accommodation/Expenses: Bristol-Myers Squibb; Honoraria (self): Lilly; Honoraria (self): Roche; Honoraria (self): Novartis; Honoraria (self): Takeda. N. Reguart: Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Pfizer; Advisory/Consultancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca; Advisory/Consultancy, Speaker Bureau/Expert testimony: Bristol-Myers Squibb; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: MSD; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche. A.S. Mansfield: Advisory/Consultancy: Trovagene; Advisory/Consultancy: Genentech; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy, Travel/Accommodation/Expenses: AbbVie; Travel/Accommodation/Expenses: Roche; Research grant/Funding (institution): Novartis. A. Robeva: Shareholder/Stockholder/Stock options, Full/Part-time employment: Novartis. S. Ghebremariam: Shareholder/Stockholder/Stock options, Full/Part-time employment: Novartis. M. Waldron-Lynch: Shareholder/Stockholder/Stock options, Full/Part-time employment: Novartis. M. Akimov: Shareholder/Stockholder/Stock options, Full/Part-time employment: Novartis. N. Nwana: Research grant/Funding (self), Shareholder/Stockholder/Stock options, Full/Part-time employment: Novartis. M. Giovannini: Shareholder/Stockholder/Stock options, Full/Part-time employment: Novartis. J. Wolf: Honoraria (self), Advisory/Consultancy: AbbVie; Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Bristol-Myers Squibb; Honoraria (self), Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Chugai Pharma; Advisory/Consultancy: Ignyta; Advisory/Consultancy: Lilly; Honoraria (self), Advisory/Consultancy: MSD Oncology; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Research grant/Funding (self): Pfizer; Honoraria (self), Advisory/Consultancy: Roche; Advisory/Consultancy, Research grant/Funding (self): Janssen; Advisory/Consultancy: Loxo/Lilly; Advisory/Consultancy: Blueprint Medicines; Advisory/Consultancy: Amgen; Advisory/Consultancy: Takeda; Advisory/Consultancy: Amgen.